Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson
- PMID: 15203087
- DOI: 10.1016/S1359-6446(04)03160-5
Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson
Abstract
Currently Acting Deputy Commissioner for Operations at FDA, Janet Woodcock has served as Director, Center for Drug Evaluation and Research at FDA since 1994. She previously served in other positions in FDA including Director, Office of Therapeutics Research and Review and Acting Deputy Director, Center for Biologics Evaluation and Research. She received her MD from Northwestern Medical School and held faculty appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.
Similar articles
-
Interview with Janet Woodcock.Bioanalysis. 2010 Sep;2(9):1535-8. doi: 10.4155/bio.10.113. Bioanalysis. 2010. PMID: 21083281
-
Interview with Janet Woodcock: progress on the FDA's critical path initiative.Biomark Med. 2009 Dec;3(6):671-3. doi: 10.2217/bmm.09.72. Biomark Med. 2009. PMID: 20477704
-
Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.Fed Regist. 1991 Nov 21;56(225):58758-9. Fed Regist. 1991. PMID: 10115699
-
Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.Drug Discov Today. 2006 Oct;11(19-20):945-51. doi: 10.1016/j.drudis.2006.08.011. Epub 2006 Sep 7. Drug Discov Today. 2006. PMID: 16997146 Review.
-
The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.Clin Pharmacol Ther. 2010 May;87(5):530-3. doi: 10.1038/clpt.2010.27. Clin Pharmacol Ther. 2010. PMID: 20407457 Review.
Cited by
-
A novel hybrid framework for metabolic pathways prediction based on the graph attention network.BMC Bioinformatics. 2022 Sep 28;23(Suppl 5):329. doi: 10.1186/s12859-022-04856-y. BMC Bioinformatics. 2022. PMID: 36171550 Free PMC article.
-
Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.Pharm Rev. 2010 Feb 3;8(1):1-9. Pharm Rev. 2010. PMID: 21643531 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources